<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03635671</url>
  </required_header>
  <id_info>
    <org_study_id>DIRECTION</org_study_id>
    <nct_id>NCT03635671</nct_id>
  </id_info>
  <brief_title>Diabetic Retinopathy and Subclinical Signs of Disease Transition</brief_title>
  <acronym>DIRECTION</acronym>
  <official_title>Diabetic Retinopathy and Subclinical Signs of Disease Transition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of diabetes mellitus (DM) is increasing worldwide. Diabetic retinopathy is the
      most prevalent complication of DM and a leading cause of visual impairment. Some factors are
      known to temporarily aggravate or improve diabetic retinopathy, but underlying
      pathophysiologic factors are still unknown. High-resolution imaging techniques of the retina
      and its supplying vascular networks now allow novel insight to subtle changes that cannot be
      appreciated in standard fundus examination. In detail, the investigators image study patients
      with optical coherence tomography (OCT) - technology, that provides morphological information
      of retinal structure and the supplying vessels in a non-invasive way. Retinal layer thickness
      as well as capillary density will be quantified and followed in patients that are in a
      critical period of disease transition to better understand the process of diabetic
      retinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unexpected poor enrollment
  </why_stopped>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Actual">July 15, 2019</completion_date>
  <primary_completion_date type="Actual">July 15, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Perfusion density</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change of perfusion density of the macula evaluated within the 9 ETDRS subfields for the superior and inferior vascular plexus separately.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perfusion density</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change of perfusion density of the macula evaluated within the 9 ETDRS subfields for the superior and inferior vascular plexus separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retinal layer thickness</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Mean change in retinal layer thickness of all retinal layers separately</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Intensified blood glucose control</arm_group_label>
    <description>Patients with diabetes mellitus type 2 and poor blood sugar control that are introduced to insulin or GLP-1 therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nephropathy</arm_group_label>
    <description>Patients that are introduced to hemodialysis or renal transplantation secondary to renal failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography Angiography</intervention_name>
    <description>Retinal scans will be acquired at each follow up visit</description>
    <arm_group_label>Intensified blood glucose control</arm_group_label>
    <arm_group_label>Nephropathy</arm_group_label>
    <other_name>Optical Coherence Tomography</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with diabetes type 1 or 2 that enter a critical period of possible disease
        transition will be recruited in a tertiary referral center.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes mellitus type 1 or 2

          -  Age 18-90

        Exclusion Criteria:

          -  Media opacities like cataract or vitreous hemorrhage

          -  Active intraocular inflammation (grade trace or above) in either eye like infectious
             conjunctivitis, keratitis, scleritis, endophthalmitis as well as idiopathic or
             autoimmune-associated uveitis in either eye

          -  Structural damage to the center of macula in the study eye

          -  Atrophy of retinal pigment epithelium, subretinal fibrosis, laser scar within foveal
             avascular zone (FAZ) or organized hard exudate plaques

          -  Ocular disorders in the study eye including retinal vascular occlusion, retinal
             detachment, macular hole, choroidal neovascularization, macula dystrophies

          -  Intraocular surgery (including cataract surgery, YAG laser capsulotomy) in the study
             eye within 3 months preceding Day 0, or history of corneal transplantation in the
             study eye

          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg
             despite treatment with anti‐glaucoma medication)or history of glaucoma filtration
             surgery

          -  Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality
             to be analyzed and graded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Maberley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of the Department of Ophthalmology and Visual Science, UBC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Care Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 3N9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 15, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2018</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>David Maberley</investigator_full_name>
    <investigator_title>MD, FRCSC</investigator_title>
  </responsible_party>
  <keyword>Imaging</keyword>
  <keyword>Diabetes</keyword>
  <keyword>OCTA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

